enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $17.24, but opened at $17.75. enGene shares last traded at $17.50, with a volume of 4,666 shares trading hands.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on ENGN. Leerink Partnrs restated an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. Morgan Stanley assumed coverage on shares of enGene in a research note on Friday, March 8th. They set an “overweight” rating and a $40.00 price target on the stock. UBS Group started coverage on shares of enGene in a report on Thursday. They issued a “buy” rating and a $37.00 price objective on the stock. Finally, SVB Leerink started coverage on shares of enGene in a report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price target on the stock.
View Our Latest Research Report on enGene
enGene Trading Down 2.5 %
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in ENGN. Citadel Advisors LLC purchased a new position in enGene in the fourth quarter worth approximately $185,000. Goldman Sachs Group Inc. acquired a new stake in enGene during the fourth quarter worth approximately $346,000. Royal Bank of Canada acquired a new stake in enGene during the fourth quarter worth approximately $349,000. Vivo Capital LLC acquired a new stake in enGene during the fourth quarter worth approximately $6,264,000. Finally, Omega Fund Management LLC acquired a new position in shares of enGene in the 4th quarter valued at $10,441,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Read More
- Five stocks we like better than enGene
- What is the Hang Seng index?
- 3 Value Stocks Too Small For Buffett’s Portfolio
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- ESG Stocks, What Investors Should Know
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.